Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 506879 | NSE Symbol : GUJTHEM | ISIN : INE942C01045 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
15-May-2025	20-May-2025	Final Dividend	Gujarat Themis Biosyn Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve audited financial results for the quarter and year ended 31st March 2025 The Board of Directors at its meeting held today, have inter alia, transacted the following items of business and taken the decisions as under: 1. Approved the Audited Financial Results for the quarter and year ended 31st March, 2025. A copy of Audited Financial Results for the quarter and year ended 31st March, 2025 is attached herewith. 2. Recommended final dividend of Re. 0.67 i.e. @ 67% per equity share having face value of Re.1/- each aggregating to Re.7,30,06,728 for the Financial Year ended 31st March, 2025. The payment is subject to the approval of shareholders at the ensuing Annual General Meeting. Kindly refer attachment for further details Read less.. (As Per BSE Announcement Dated on :20.05.2025)
07-Feb-2025	14-Feb-2025	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 ,inter alia, to consider and approve the Unaudited financial results and Limited Review Report for the Quarter and Nine months ended 31st December, 2024. Please refer to the attachment. (As Per BSE Announcement Dated on 14.02.2025)
18-Nov-2024	18-Nov-2024	Scheme of Amalgamation	Please refer to the attachment.
18-Oct-2024	25-Oct-2024	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve Please refer to our intimation of Board Meeting scheduled on 25th October 2024. Please refer to the attachment. Please refer to the attachment. (As Per BSE Announcement Dated on 25.10.2024)
16-Jul-2024	26-Jul-2024	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve the unaudited financial results for the quarter ended 30th June 2024. Please refer to the attachment (As Per BSE Announcement dated on 26.07.2024)
03-May-2024	14-May-2024	Accounts	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve 1) To consider and approve the Audited Financial Results for the Quarter/Year ended on 31st March 2024. 2) To consider recommending Dividend if any on the equity shares of the Company for the financial year 2023-24. 3) To consider proposal for the Issue of Bonus Shares to the equity shareholders of the Company Please find our intimation on the captioned subject. Appointment of Mr. Hitesh Gajaria (DIN: 10044310) as an Additional Non-Executive Independent Director and Mr. Kim Do Seon as Chief Technology Officer of the Company w.e.f. 14th May, 2024. (As Per BSE Announcement Dated on 14.05.2024)
29-Jan-2024	10-Feb-2024	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Un-audited Financial Results for the quarter ended on 31st December 2023. Please refer the attached intimation Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Saturday, 10th February, 2024, has inter-alia approved the following: a) The Unaudited Standalone Financial Results for the Quarter ended 31st December, 2023. A copy of Unaudited Standalone Financial Results for the Quarter ended 31st December, 2023 together with Limited Review Report is enclosed herewith. b) Declaration of an Interim Dividend for the Financial Year 2023-24 of ? 0.75/- (Rupee Seventy-Five paise only) per equity share having face value of ? 1/- i.e. 75.00% aggregating to ? 5,44,82,632.50/- (Rupees Five Crore Forty-Four Lakhs Eighty-Two Thousand Six Hundred and Thirty-Two and Fifty Paise only) c) The Record Date for the purpose of interim dividend is 22nd February, 2024. (As per BSE Announcement Dated on 10/02/2024)
25-Oct-2023	04-Nov-2023	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve the Un-audited Financial Results for the quarter and half year ended on 30th September 2023. Further in continuation of our Letter dated 27th September 2023 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors / Designated Employees from the opening of the trading hours on Sunday 1st October 2023 which shall remain closed till the closure of trading hours on 6th November 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Saturday, 4th November, 2023, has inter-alia approved the following: a) The Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023. A copy of Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023 together with Limited Review Report is enclosed herewith. b) the proposal to enter into Master Service Agreement with its Related Party, viz. Themis Medicare Limited. The details required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 read with Regulation 30A of the Listing Regulations are enclosed as Annexure - I. This may be taken as compliance under the Listing Regulations. (As Per BSE Announcement Dated on 04.11.2023)
02-Aug-2023	10-Aug-2023	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Saturday 12th August 2023 inter alia to consider and approve the Un-audited Standalone Financial Results for the Quarter ended on 30th June 2023. Further in continuation of our Letter dated 28th June 2023 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 1st July 2023 which shall remain closed till the closure of trading hours on Monday 14th August 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve This has reference to our letter dated 02nd August, 2023 informing that a meeting of the Board of Directors of Gujarat Themis Biosyn Ltd. (''the Company'') to be held on Saturday, 12th August, 2023 inter alia, to consider and approve the Un-audited Standalone Financial Results for the Quarter ended on 30th June, 2023. The said meeting is now preponed and rescheduled and will now be held on Thursday, 10th August,2023. (As Per BSE Announcement Dated on 03-08-2023) The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results of the Company for the Quarter ended 30th June, 2023. A copy of Unaudited Financial Results of the Company for the Quarter ended 30th June, 2023 together with Limited Review Report is enclosed herewith. This may be taken as compliance under the Listing Regulations. Please find attached a copy of unaudited financial results along with Limited Review Report for the quarter ended June 30, 2023. (As Per BSE Announcement Dated on 10/08/2023)
04-May-2023	13-May-2023	Accounts	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2023 inter alia to consider and approve Please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Saturday 13.05.2023 inter alia to transact the following business: 1.To consider the Audited Financial Results for the Quarter/Year ended on 31.03.2023. 2.To consider recommending Dividend if any on the equity shares of the Company for the financial year 2022-23. Further in continuation of our Letter dated 27.03.202 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 1stApril 2023 which shall remain closed till the closure of trading hours on Monday 15th May 2023 (both days inclusive) i.e. till the completion of 48 hours after conclusion of the Board meeting as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. Audited Results & Stock Split & Final Dividend (As per BSE Bulletin dated on 04/05/2023) The Board of Directors at its meeting held today, considered and approved the following matters: 1. Approved the Audited Financial Results for the Quarter and Year ended 31st March, 2023. A copy of Audited Financial Results for the Quarter and Year ended 31st March, 2023 is enclosed herewith. (Annexure I). 2. Appointed CS Ketan R. Shirwadkar (ACS 37829) or failing him, CS Prakash Nagringrekar (ACS 5941), Designated Partners of HSPN & Associates LLP, Practicing Company Secretary, Mumbai, as the Scrutinizer for conducting E-Voting and Polling at the 42nd Annual General Meeting. 3. Recommended dividend for Financial Year ended 31.03.2023 of Rs.1/- i.e. @ 20% per equity share having face value of Rs.5/- , aggregating to Rs. 1,45,28,702. The payment is subject to the approval of shareholders at the ensuing AGM 4. Considered the appointment of M/s. RAJA DUTTA & CO., Cost Accountant as the Cost Auditors of the Company. 6. The 42nd Annual General Meeting ('AGM') of the Company will be held on Saturday, 09th September, 2023 at 10:30 AM in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. 7. The Register of Members and Share Transfer Books of the Company will remain closed for payment of dividend and AGM from Saturday, 02nd September, 2023 to Saturday, 09th September, 2023 (both days inclusive). 3. Recommended dividend for Financial Year ended 31.03.2023 of Rs.1/- i.e. @ 20% per equity share having face value of Rs.5/- , aggregating to Rs. 1,45,28,702. The payment is subject to the approval of shareholders at the ensuing AGM (As Per BSE Announcement Dated on 13.05.2023)
27-Jan-2023	03-Feb-2023	Quarterly Results	Quarterly Results GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 ,inter alia, to consider and approve With respect to the captioned subject, please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Friday 03rd February, 2023 inter alia, to consider, the Un-audited Standalone Financial Results for the Quarter and nine months ended on 31st December, 2022. Further, in continuation of our Letter dated 26th December 2022, the Trading Window in respect of dealing in the Company's Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Sunday, 1st January, 2023, which shall remain closed till the closure of trading hours on 05th February, 2023 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time. (As Per BSE Announcement dated on 27.01.2023) The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results of the Company for the Quarter ended 31st December, 2022. A copy of Unaudited Financial Results of the Company for the Quarter ended 31st December, 2022 together with Limited Review Report is enclosed herewith. This may be taken as compliance under the Listing Regulations. The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results of the Company for the Quarter ended 31st December, 2022. A copy of Unaudited Financial Results of the Company for the Quarter ended 31st December, 2022 together with Limited Review Report is enclosed herewith. This may be taken as compliance under the Listing Regulations. (As Per BSE Announcement Dated on 03/02/2023)
05-Jan-2023	05-Jan-2023	Change in Other Executives	The Board of Directors at its meeting held today, considered and approved the appointment of Mr. Tapas Guha Thakurata as the Chief Executive Officer (CEO) of the Company- Key Managerial Personnel under the provisions of the Companies Act, 2013 and rules there under. We have annexed herewith the disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 read with SEBI circular no CIR/CFD/CMD/4/2015 dated 09th September, 2015 relating to appointment of Mr. Tapas Guha Thakurata as the CEO.(Annexure I) This may be taken as compliance under the Listing Regulations.
16-Nov-2022	21-Nov-2022	Interim Dividend	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/11/2022 inter alia to consider and approve With reference to captioned subject this is to inform you that the meeting of Board of Directors of Gujarat Themis Biosyn Ltd. will be held on Monday 21st November 2022 inter alia to consider a proposal relating to declaration of Interim Dividend for the financial year 2022-2023 if any. Further as per Companys Code of Conduct for Prevention of Insider Trading framed pursuant to SEBI ( Prohibition of Insider Trading ) Regulation 2015 the trading window for dealing in the securities of the company will remain closed for specified person from November 16 2022 to November 23 2022 (both days inclusive). This is for your information and record. With reference to captioned subject this is to inform you that the meeting of Board of Directors of Gujarat Themis Biosyn Ltd. will be held on Monday, 21st November, 2022, inter alia to consider a proposal relating to declaration of Interim Dividend for the financial year 2022-2023, if any. Further, as per Company''s Code of Conduct for Prevention of Insider Trading, framed pursuant to SEBI ( Prohibition of Insider Trading ) Regulation, 2015, the trading window for dealing in the securities of the company will remain closed for specified person from November 16, 2022 to November 23, 2022 (both days inclusive). This is for your information and record. Meeting Commencement Time : 10:00 A.M Meeting Conclusion Time : 10:51 A.M The Board of Directors at its meeting held today, considered and approved the following: 1. Declaration of an Interim Dividend for the Financial Year 2022-23 of 4.40/- (Rupees Four and forty paise only) per equity share having face value of 5/- i.e. 88% aggregating to 6,39,26,289/- (Rupees Six Crore Thirty Nine lakhs twenty six thousand two hundred eighty nine only) 2. The Record date for the same is 2nd December,2022 This may be taken as compliance under the Listing Regulations. Kindly take the same on record. (As Per BSE Announcement Dated on 21.11.2022)
28-Oct-2022	07-Nov-2022	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Wednesday 7th November 2022 inter alia to consider the Un-Audited Financial Results for the Quarter/Half year ended on 30th September 2022. Further in continuation of our Letter dated 27th September 2022 the Trading Window in respect of dealing in the Companys Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Saturday 1st October 2022 which shall remain closed till the closure of trading hours on 9th November 2022 (both days inclusive) i.e. till the completion of 48 hours after conclusion of the Board meeting as per the policy for prohibition of Insider Trading ('the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time. In continuation to our letter dated 28th October, 2022, about the intimation of Board Meeting to be held on, 7th November, 2022. There was a typographical error where by Monday was inadvertently typed as Wednesday. This has to be read as Monday, 7th November, 2022 instead of Wednesday. (As Per BSE Announcement Dated on 31.10.2022) The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results of the Company for the Quarter / Half year ended 30th September, 2022. A copy of Unaudited Financial Results of the Company for the Quarter / Half year ended 30th September, 2022 together with Limited Review Report is enclosed herewith. This may be taken as compliance under the Listing Regulations. Kindly take the same on record. (As Per BSE Announcement Dated on 07.11.2022) In terms of Regulation 47 of the SEBI (LODR) Regulations, 2015 the Company has published the Unaudited Financial Results for the quarter and half year ended September 30, 2022 in ''Western Times'' (English) edition dated Tuesday, November 8, 2022 & in ''Western Times'' (Gujarati) edition dated Tuesday, November 8, 2022. Further, in pursuance of Regulation 30 read with Schedule III (A) (12) please find enclosed the copy of Newspaper articles as published in above mentioned newspapers. (As Per BSE Announcement Dated on 09/11/2022)
19-Jul-2022	27-Jul-2022	Quarterly Results	GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2022 inter alia to consider and approve With respect to the captioned subject please be informed that a meeting of the Board of Directors of Gujarat Themis Biosyn Limited is scheduled to be held on Wednesday 27th July 2022 inter alia to consider the Un-Audited Financial Results for the quarter ended 30th June 2022. Kindly take the same on record. The Board of Directors at its meeting held today, considered and approved the following matters: 1. Unaudited Financial Results of the Company for the Quarter ended 30thJune, 2022. A copy of Unaudited Financial Results of the Company for the Quarter ended 30th June, 2022 together with Limited Review Report is enclosed herewith. 2. Confirmed the time, and date of the 41st Annual General Meeting which will be held on Wednesday, 7th September, 2022 at 12:00 Noon. 3. Closure of Register of Members and Share Transfer Books from Wednesday ,31st August, 2022 to Wednesday ,7th September, 2022 for the purpose of 41st Annual General Meeting and payment of dividend for the financial year 2021-22, if approved at the ensuing Annual General Meeting. This has reference to the Unaudited Financial results for the quarter ended June 30, 2022 of our Company as approved by the Board of Directors and uploaded on website on July 27, 2022. Under the Serial No. IV Total expenses should be read as ? 2,279.80 Lakhs instead of ? 2,279.78 Lakhs and the consequential changes of the same is reflected in the columns V, VII, IX, and XI. The said inadvertent error is hereby rectified and we now resubmit the correct Financial Results for the quarter ended June 30, 2022 which may kindly be taken on record and be uploaded on the Exchange website to disseminate the correct information to investors. We regret the inconvenience caused. (As Per BSE Announcement Dated on 27.07.2022)

1 2

LOGIN HERE

Gujarat Themis Biosyn Ltd

Board Meeting